

# Daria O'reilly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11566784/publications.pdf>

Version: 2024-02-01

44  
papers

1,131  
citations

430874

18  
h-index

414414

32  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1752  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit. <i>Journal of Critical Care</i> , 2017, 41, 138-144.	2.2	129
2	Safety of Tissue Expander/Implant versus Autologous Abdominal Tissue Breast Reconstruction in Postmastectomy Breast Cancer Patients. <i>Plastic and Reconstructive Surgery</i> , 2014, 133, 234-249.	1.4	105
3	Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. <i>Current Medical Research and Opinion</i> , 2007, 23, 671-682.	1.9	92
4	Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. <i>ClinicoEconomics and Outcomes Research</i> , 2011, 3, 89.	1.9	84
5	Systematic Review and Meta-analysis of the Benefits of Out-of-Hospital 12-Lead ECG and Advance Notification in ST-Segment Elevation Myocardial Infarction Patients. <i>Annals of Emergency Medicine</i> , 2014, 64, 176-186.e9.	0.6	51
6	A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment. <i>Pharmacoeconomics</i> , 2010, 28, 255-277.	3.3	48
7	Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. <i>Cost Effectiveness and Resource Allocation</i> , 2010, 8, 14.	1.5	45
8	Cost-effectiveness analysis of elective endovascular repair compared with open surgical repair of abdominal aortic aneurysms for patients at a high surgical risk: A 1-year patient-level analysis conducted in Ontario, Canada. <i>Journal of Vascular Surgery</i> , 2008, 48, 779-787.	1.1	41
9	Systematic Review on the Patient-Reported Outcomes of Tissue-Expander/Implant vs Autologous Abdominal Tissue Breast Reconstruction in Postmastectomy Breast Cancer Patients. <i>Journal of the American College of Surgeons</i> , 2014, 218, 1038-1048.	0.5	41
10	A Cost-Effectiveness Model Comparing Endovascular Repair to Open Surgical Repair of Abdominal Aortic Aneurysms in Canada. <i>Value in Health</i> , 2009, 12, 245-252.	0.3	37
11	Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 21.	1.9	32
12	Prevalence, Total and Excess Costs of Diabetes and Related Complications in Ontario, Canada. <i>Canadian Journal of Diabetes</i> , 2009, 33, 35-45.	0.8	31
13	The Effect of Bariatric Surgery on Mobility, Health-Related Quality of Life, Healthcare Resource Utilization, and Employment Status. <i>Obesity Surgery</i> , 2017, 27, 349-356.	2.1	30
14	Cost-effectiveness of a shared computerized decision support system for diabetes linked to electronic medical records. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2012, 19, 341-345.	4.4	27
15	Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 55-69.e1.	2.3	22
16	Clinical outcomes and health care utilization pre- and post-laparoscopic radiofrequency ablation of symptomatic fibroids and laparoscopic myomectomy: a randomized trial of uterine-sparing techniques (TRUST) in Canada. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 201-212.	1.9	22
17	Long-Term Cost-utility Analysis of a Multidisciplinary Primary Care Diabetes Management Program in Ontario. <i>Canadian Journal of Diabetes</i> , 2007, 31, 205-214.	0.8	21
18	Steps toward improving ethical evaluation in health technology assessment: a proposed framework. <i>BMC Medical Ethics</i> , 2016, 17, 34.	2.4	20

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of reducing wait times for cataract surgery in Ontario. Canadian Journal of Ophthalmology, 2008, 43, 213-217.	0.7	19
20	Effects of study design and trends for EVAR versus OSR. Vascular Health and Risk Management, 2008, Volume 4, 1011-1022.	2.3	19
21	Health Technology Assessment and Primary Data Collection for Reducing Uncertainty in Decision Making. Journal of the American College of Radiology, 2009, 6, 332-342.	1.8	18
22	BARRIERS AND FACILITATORS INFLUENCING ETHICAL EVALUATION IN HEALTH TECHNOLOGY ASSESSMENT. International Journal of Technology Assessment in Health Care, 2015, 31, 113-123.	0.5	17
23	Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 127-137.	1.9	16
24	Comparative Efficacy of Angiotensin II Antagonists in Essential Hypertension: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. Heart Lung and Circulation, 2018, 27, 666-682.	0.4	14
25	Effect of Diabetes Health Coaching on Glycemic Control and Quality of Life in Adults Living With Type 2 Diabetes: A Community-Based, Randomized, Controlled Trial. Canadian Journal of Diabetes, 2021, 45, 594-600.	0.8	13
26	Calculating Utility Decrements Associated With an Adverse Event: Marginal Tobit and CLAD Coefficients Should Be Used With Caution. Medical Decision Making, 2011, 31, 790-799.	2.4	13
27	Economic evaluations conducted by Canadian health technology assessment agencies: Where do we stand?. International Journal of Technology Assessment in Health Care, 2008, 24, 437-444.	0.5	12
28	Effect of Computer-Generated Tailored Feedback on Glycemic Control in People With Diabetes in the Community. Diabetes Care, 2011, 34, 1794-1798.	8.6	12
29	Impact of the 1997 Canadian Guidelines on the Conduct of Canadian-Based Economic Evaluations in the Published Literature. Value in Health, 2010, 13, 328-334.	0.3	10
30	Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 513-521.	1.4	10
31	DRUG DISINVESTMENT FRAMEWORKS: COMPONENTS, CHALLENGES, AND SOLUTIONS. International Journal of Technology Assessment in Health Care, 2017, 33, 261-269.	0.5	10
32	Should Endovascular Repair Be Reimbursed for Low Risk Abdominal Aortic Aneurysm Patients? Evidence from Ontario, Canada. International Journal of Vascular Medicine, 2011, 2011, 1-10.	1.0	9
33	Sentinel Lymph Node Biopsy in Vulvar Cancer: A Health Technology Assessment for the Canadian Health Care Context. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 1053-1065.	0.7	9
34	Conditionally Funded Field Evaluations and Practical Trial Design Within a Health Technology Assessment Framework. Journal of the American College of Radiology, 2009, 6, 324-331.	1.8	7
35	Conditionally Funded Field Evaluations: PATHs Coverage with Evidence Development Program for Ontario. Value in Health, 2010, 13, S8-S11.	0.3	7
36	The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes. Canadian Journal of Diabetes, 2019, 43, 477-482.	0.8	7

#	ARTICLE	IF	CITATIONS
37	Health Technology Assessment for Radiologists: Basic Principles and Evaluation Framework. Journal of the American College of Radiology, 2009, 6, 299-306.	1.8	6
38	General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 379-384.	1.4	4
39	Feasibility of an altruistic sperm donation program in Canada: results from a population-based model. Reproductive Health, 2017, 14, 8.	3.1	4
40	Excess Risk of Mortality and Complications Associated with Newly Diagnosed Cases of Diabetes in Ontario, Canada. Canadian Journal of Diabetes, 2009, 33, 93-104.	0.8	3
41	Cost-effectiveness of 64-slice CT angiography compared to conventional coronary angiography based on a coverage with evidence development study in Ontario. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 675-690.	1.4	3
42	Basics of Health Technology Assessment. Methods in Molecular Biology, 2008, 473, 263-283.	0.9	3
43	Health Technology Agency insights: informing modification of a qualitative benefit risk framework for Health Technology Reassessment of prescription medications. International Journal of Technology Assessment in Health Care, 2019, 35, 384-392.	0.5	2
44	In search of the evidentiary foundation of published Canadian economic evaluations (2001-2006). International Journal of Technology Assessment in Health Care, 2009, 25, 214-221.	0.5	1